Safety and clinical effectiveness of intravitreal administration of bevacizumab (Lumiere^®) in patients with neovascular age-related macular degeneration.

ABSTRACT: The present study was an open-label, prospective, uncontrolled and multicenter clinical trial to investigate the safety and effectiveness of bevacizumab (Lumiere^®) administered by the intravitreal route for the treatment of neovascular age-related macular degeneration (nAMD). A total of 22 patients without previous treatment with anti-vascular endothelial growth factor were recruited. Monthly therapy with 1.25 mg intravitreal bevacizumab was applied. Adverse events (AE), visual acuity (VA) and central retinal thickness (CRT) were assessed at baseline, day 1 and day 28 after each injection. A total of 87 AEs were reported; most of them were not serious (96.6%), expected (65.5%) and occurred after the third injection (56.3%). The most frequent AE was 'conjunctival hemorrhage' (29.

SUBMITTER: Benisek DA 

PROVIDER: S-EPMC7571337 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature